SCHEMBL4983030

SCHEMBL4983030

CC(C)c1ccccc1CC(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
LPAR1 Q92633 2/20 0.45
GABRA1 P14867 3/20 0.42
GABRB2 P47870 2/20 0.42
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
NOS2 P35228 2/20 0.39
LMNA P02545 2/20 0.39
FAAH O00519 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29718608 1.00 HSP90AA1 (0.47) HSP90AA1HSP90AB1LPAR1GABRA1GABRB2
SCHEMBL20681290 0.84 HSP90AA1 (0.41) HSP90AA1HSP90AB1GABRA1GABRB2SLC6A2
SCHEMBL2554055 0.82 AKR1B1 (0.55) LPAR1GABRA1GABRB2LMNACYP1A2
SCHEMBL9272837 0.82 LPAR1 (0.46) LPAR1GABRA1GABRB2SLC6A2SLC6A4
SCHEMBL10864953 0.82 L3MBTL1 (0.46) LPAR1GABRA1GABRB2SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL10582878 0.81 AKR1B1 (0.53) LPAR1GABRA1GABRB2LMNACYP1A2
SCHEMBL29718697 0.81 NPSR1 (0.36) HSP90AA1HSP90AB1SLC6A3LMNACA2
SCHEMBL17975834 0.79 LPAR1 (0.44) LPAR1GABRA1GABRB2SLC6A2SLC6A4
SCHEMBL10339218 0.79 AKR1B1 (0.46) CA2CYP1A2CYP3A4TSHRBLM
SCHEMBL2817756 0.78 GABRA1 (0.55) HSP90AA1HSP90AB1LPAR1GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188869-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2021-06-24 US disclosed
US-10927125-B2 Substituted cinnolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2021-02-23 US disclosed
EP-3458443-B1 AROMATIC SULFONAMIDE DERIVATIVES Bayer Pharma AG (DE) 2020-08-19 EP disclosed
US-20200102321-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2020-04-02 US disclosed
CN-106572658-B Molecule and relative intermediate, composition and method with certain disinsection efficiencies 美国陶氏益农公司 2019-11-08 CN disclosed
CN-110372530-A A kind of compound of the structure of substituted-phenyl containing α and preparation method thereof and elimination agent 郑州大学 2019-10-25 CN disclosed
CN-109788759-A Pesticidal combination and method 美国陶氏益农公司 2019-05-21 CN disclosed
CN-106572658-A Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto 美国陶氏益农公司 2017-04-19 CN disclosed
CN-104936954-A compounds and methods of use thereof AGIOS PHARMACEUTICALS INC 2015-09-23 CN disclosed
US-20130289083-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION 2013-10-31 US disclosed
US-20110053941-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-03-03 US disclosed
US-7388111-B2 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC (US) 2008-06-17 US disclosed
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188869-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS HSP90AA1 4244/4885HSP90AB1 3687/4885LPAR1 646/4885
US-10927125-B2 Substituted cinnolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS HSP90AA1 4699/4885HSP90AB1 4318/4885LPAR1 1650/4885
US-20110053941-A1 IDO Inhibitors IDO1, IDO2, INMT HSP90AA1 3786/4885HSP90AB1 3086/4885LPAR1 3228/4885
US-20200102321-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS HSP90AA1 4248/4885HSP90AB1 3884/4885LPAR1 1615/4885
US-20070088053-A1 Non-nucleoside reverse transcriptase inhibitors SAMHD1, QTRT1, RTF1 HSP90AA1 2699/4885HSP90AB1 2414/4885LPAR1 1478/4885
US-20130289083-A1 IDO Inhibitors IDO1, IDO2, INMT HSP90AA1 3139/4885HSP90AB1 2435/4885LPAR1 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.